CO44194

 The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, RO7247669, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).

Acronym:

CO44194

ACTRN/NCT /ethics:

NCT05852691

Scientific title:

A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Sponsor / Cooperative group:

Hoffmann-La Roche